Evidence map›Paper›PMID 41501921›Full record

ReviewJournal of experimental & clinical cancer research : CR2026

Modeling CAF-tumor interactions to overcome therapy resistance.

Jakub Gubala, Daniel Benamran, Petros Tsantoulis, Valentin Mieville, Massimo Valerio, Patrycja Nowak-Sliwinska

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jakub GubalaCancer Systems Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, 1211, Switzerland.
Daniel BenamranDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.
Petros TsantoulisDepartment of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Valentin MievilleCancer Systems Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, 1211, Switzerland.
Massimo ValerioDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.
Patrycja Nowak-SliwinskaCancer Systems Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, 1211, Switzerland. Patrycja.Nowak-Sliwinska@unige.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) represent an interesting component of the tumor microenvironment, playing a crucial role in cancer progression, metastasis, and treatment resistance. This review provides a comprehensive overview of identified subtypes across various cancer types, highlighting their inter-tumor heterogeneity, plasticity, and function of the different CAF phenotypes. With a focus on renal cell carcinoma, we reviewed the correlations between CAF markers, disease progression, and treatment outcomes. This approach underlined the existence of CAF-induced drug resistance and therapeutic strategies that can be utilized to overcome this extrinsic resistance. A major focus of this review is the role of CAFs in inducing drug resistance, a phenomenon observed in both in vivo and in vitro cancer models. We discuss the integration of CAFs in several in vitro co-culture systems cultivated in two- and three-dimensional models, as well as their contributions to deciphering CAF-tumor crosstalk. These platforms better recapitulate the tumor microenvironment, reflecting CAF-induced therapeutic resistance. Ultimately, this review underlines the crucial role of CAF-incorporated co-culture systems in advancing drug development, especially in the context of tissue- and subtype-specific CAF targeting.

Indexed as

Cancer-Associated FibroblastsDrug Resistance, NeoplasmNeoplasmsAnimalsCoculture TechniquesHumansTumor MicroenvironmentCancer-associated fibroblastsClear cell renal cell carcinomaCombined treatmentThe extracellular matrixTumor microenvironment

Identifiers

PMID41501921
PMCPMC12882138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.